Loading
institutionsInstitution
Leeds Cancer Centre, St James's University Hospital
One of the largest cancer centres in the UK, known for colorectal cancer pathology and trials, melanoma research, myeloma and MR-guided radiotherapy.
Also called: Leeds Teaching Hospitals NHS TrustBexley WingLeeds Institute of Medical Research
Overview
The Leeds Cancer Centre at St James's University Hospital is among the UK's largest single-site cancer centres, serving Yorkshire with radiotherapy, surgery, haematology and paediatric oncology. University of Leeds research includes Philip Quirke's pathology work that established circumferential resection margin assessment in rectal cancer, the Leeds Clinical Trials Research Unit that ran FOxTROT (neoadjuvant chemotherapy in colon cancer) and UK myeloma trials, and melanoma epidemiology and genetics. Leeds was an early UK adopter of the Elekta Unity MR-linac and hosts the Leeds Institute of Medical Research at St James's and a CRUK Centre. The centre also has a national profile in teenage and young adult cancer and in health data research.
Location
Leeds, GB
Type
hospital · University of Leeds
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#38 · 64 points (0 Newsweek + 0 NCI + 64 from 32 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to St James's University Hospital, including child institutions. 363 works · 6,609 citations · 83% open access · 16% clinical trials · 6% reviews.
Oncology works per year
802022
822023
582024
832025
602026
Most works
- Galina Velikova41 works
- Jenny F. Seligmann27 works
- Nicholas P. West26 works
- Philip Quirke23 works
- Florien Boele17 works
- Kieran Horgan16 works
- Michel Seymour15 works
- Andrew M. Smith15 works
- Hugo Vachon14 works
- Mogens Grøenvold14 works
Most cited
- Colorectal cancer pathology and trials
- MR-linac radiotherapy
- Myeloma trials
- Melanoma epidemiology
- Clinical Trials Research Unit
Brendan Brown
Chief Executive, Leeds Teaching Hospitals NHS Trust
Hospital managementNHS leadershipCancer services
Chief Executive of Leeds Teaching Hospitals NHS Trust, the NHS trust that runs the Leeds Cancer Centre at St James's University Hospital.
David Sebag-Montefiore
Professor of Clinical Oncology (Audrey and Stanley Burton Chair), University of Leeds; Clinical Director, Leeds Clinical Trials Research Unit
Rectal cancer radiotherapyOrgan preservationRandomised radiotherapy trials
The Leeds clinical oncologist who led CR07, the trial that made short-course radiotherapy before surgery the standard for rectal cancer, and who now works on preserving the rectum instead of removing it.
Matt Seymour
Professor of Gastrointestinal Cancer Research, University of Leeds
Advanced colorectal cancer chemotherapyTrial strategy and designNeoadjuvant treatment of colon cancer
The Leeds oncologist behind the FOCUS trials, which asked how best to sequence chemotherapy for advanced bowel cancer, and a leader of FOxTROT, which moved chemotherapy before surgery in colon cancer.
Matthew Callister
Consultant in Respiratory Medicine, Leeds Teaching Hospitals NHS Trust; Honorary Professor, University of Leeds
Lung cancer screeningEndobronchial ultrasoundMesothelioma
The Leeds respiratory physician who ran the Yorkshire Lung Screening Trial, the trial that worked out which risk rule the NHS should use to decide who gets a screening scan.
Peter Hillmen
Emeritus Professor of Experimental Haematology, University of Leeds
Chronic lymphocytic leukaemiaMRD-guided therapyParoxysmal nocturnal haemoglobinuria
Led FLAIR, the UK trial showing MRD-guided ibrutinib plus venetoclax outperforms chemoimmunotherapy in CLL.
observationalJournal of Pathology 2016188 citations
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials
It fixes the population size for HER2-directed therapy, shows the enrichment in wild-type disease that makes reflex HER2 testing worthwhile there, and establishes that HER2 is not itself prognostic in this cancer.
meta analysisClinical Cancer Research 2014604 citations
Mismatch repair status and BRAF mutation status in metastatic colorectal cancer: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies
It fixes the metastatic prevalence figures every subsequent trial design has used, and it separates two biomarkers that travel together: BRAF, not mismatch repair deficiency, is what makes the prognosis bad.
Similar pages
- PersonDion Morton
Shares STAR-TREC, David Sebag-Montefiore, Matt Seymour, FOxTROT.
- InstitutionNewcastle Cancer Centre / Northern Centre for Cancer Care
Shares EUROPAC, AMMF, the Cholangiocarcinoma Charity, UK specialist HPB cancer centres, Basal cell carcinoma.
- InstitutionUniversity Hospital Southampton / Centre for Cancer Immunology
Shares EUROPAC, AMMF, the Cholangiocarcinoma Charity, UK specialist HPB cancer centres, Cancer Research UK.
- PersonPhilip Crosbie
Shares Matthew Callister, YLST, Lung cancer (all types), Non-small-cell lung cancer.
- InstitutionNottingham University Hospitals Cancer Centre (City Hospital)
Shares EUROPAC, UK specialist HPB cancer centres, Basal cell carcinoma, Lung cancer (all types).
- InstitutionImperial College Healthcare NHS Trust / Imperial College London Cancer Research
Shares AMMF, the Cholangiocarcinoma Charity, UK specialist HPB cancer centres, Cancer Research UK, Pancreatic ductal adenocarcinoma.
- InstitutionDerriford Hospital, University Hospitals Plymouth
Shares EUROPAC, UK specialist HPB cancer centres, Gallbladder cancer, Pancreatic ductal adenocarcinoma.
- InstitutionMorriston Hospital, Swansea
Shares EUROPAC, UK specialist HPB cancer centres, Gallbladder cancer, Pancreatic ductal adenocarcinoma.
cancers
fronts
technologies
companies
institutions
terms
trials
collections
people
key papers
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trialsMismatch repair status and BRAF mutation status in metastatic colorectal cancer: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies